Tesamorelin is one of the rare peptides in this space with an FDA-approved indication behind it: real endpoints, real randomized trials, a real disease target. That fact tends to get lost the moment tesamorelin shows up in a forum thread promising general fat loss or sharper thinking in someone who was never sick to begin with. The approved use holds up well; most of what surrounds it does not.
What it is
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), built to survive longer in circulation than the native 44-amino acid hormone does. The modification is a trans-3-hexenoic acid group added to the N-terminus, which slows the enzyme DPP-4 from degrading it before it reaches the pituitary. Marketed as Egrifta, it was approved for one narrow purpose: reducing excess visceral adipose tissue in people with HIV-associated lipodystrophy. Theratechnologies developed it out of earlier GHRH-analog research aimed at restoring the pulsatile pattern of growth hormone release the body normally uses, rather than flooding the system with GH directly.
That distinction, pulsatile release versus direct GH administration, is the same reasoning behind why GHRH analogs are generally treated as gentler on feedback loops than recombinant growth hormone itself.
Why people care
Two very different audiences pay attention to tesamorelin, and they are not asking the same question.
HIV clinicians and researchers care because lipodystrophy, the fat redistribution that accompanies long-term antiretroviral therapy, is a genuine and disfiguring metabolic complication with limited treatment options.
Everyone else got interested because “reduces visceral fat” travels well outside its original context, and GHRH’s link to growth hormone signaling makes it an easy sell for body composition, and even for cognitive framing.
A smaller research thread has tested tesamorelin in older adults on the theory that GH/IGF-1 signaling in the brain declines with age and might be restorable.
What the evidence actually splits into: solid trial data for one metabolic indication, a single small trial for cognition, and nothing at all for general fat loss in healthy people, three different amounts of evidence, not three versions of the same claim.
What’s in the literature
The approved indication
The trial that built the case for Egrifta is Falutz and colleagues’ 2007 randomized controlled trial in the New England Journal of Medicine, run over 26 weeks in HIV patients with abdominal fat accumulation. It found that tesamorelin significantly reduced visceral adipose tissue and improved lipid profiles compared with placebo[1]. Nearly every subsequent tesamorelin claim, reasonable or not, traces back to this paper.
A separate randomized trial pushed the question toward the liver. Over 12 months, tesamorelin at 2 mg once daily reduced hepatic fat fraction relative to placebo in HIV patients with non-alcoholic fatty liver disease[2]. That is a different endpoint from a CT-measured visceral fat area, but it points the same direction: in this population, on this drug, the metabolic effect replicates.
The cognitive research
Baker and colleagues ran a controlled trial of tesamorelin in adults with mild cognitive impairment and in healthy older adults, over 20 weeks. IGF-1 rose 117 percent on treatment, and the trial reported favorable cognitive effects, concentrated in executive function, in both groups[3].
That is a genuinely interesting result, but it is also a single 20-week trial. An executive-function signal in a small sample is not the same claim as “protects against dementia,” and nobody has run the multi-year trial that would let anyone say that honestly.
A useful comparison: semaglutide in the same disease
HIV-associated lipohypertrophy has recently become a testing ground for a completely different mechanism. A 32-week randomized, double-blind, placebo-controlled trial of once-weekly semaglutide, a GLP-1 receptor agonist with no relation to GHRH biology, reduced visceral adipose tissue by roughly 31 percent in people with HIV-associated lipohypertrophy[4].
Two structurally unrelated peptides, one working through GHRH, one through GLP-1, are being tested against the same fat-redistribution problem in the same patient population, using the same kind of properly randomized design. That is what a real evidence base looks like, and it’s a standard tesamorelin’s non-HIV fan base doesn’t come close to meeting.
How it’s used in research
Across the trials that have actually put tesamorelin into humans, the protocol is fairly consistent:
Route and dose: subcutaneous injection, once daily, typically 1 to 2 mg[2].
Duration in the lipodystrophy trials: 26 weeks in the pivotal Falutz trial[1], extending to 12 months in the NAFLD trial[2].
Duration in the cognitive trial: shorter, around 20 weeks, at a comparable daily subcutaneous dose[3].
Nobody has published a trial running years, so nobody has data on what sustained pituitary stimulation looks like past the one-year mark.
What’s actually known vs. assumed
Known, and replicated:
Visceral fat reduction in HIV-associated lipodystrophy, across independently designed randomized trials with different fat-based endpoints[1][2].
A downstream endocrine signature consistent with GHRH receptor activation. In the Baker trial, IGF-1 rose 117 percent[3]. In a related study of GHRH in HIV-associated NAFLD, the hormone shifted the IGF-binding-protein profile, raising IGFBP-1 and IGFBP-3 while lowering IGFBP-2 and IGFBP-6, though that paper’s own abstract stops short of reporting IGF-1 directly[5].
Assumed, not demonstrated:
Broad anti-aging or general fat-loss benefit in healthy people without HIV. This is extrapolated entirely from mechanism. No dedicated trial in a healthy, non-HIV population has tested it, and anyone selling it that way is selling extrapolation, not evidence.
A durable cognitive benefit. One 20-week trial with a favorable executive-function signal is not evidence of protection against cognitive decline.
The gap that matters: the distance between a drug that earned approval on the strength of its own trials and a drug people want to be something more, because the mechanism sounds like it should generalize.
If you want to go deeper
Start with Falutz and colleagues’ 2007 NEJM trial, still the landmark reference for the visceral fat effect[1].
Read the Lancet HIV NAFLD trial for the liver-fat data, the closest thing tesamorelin has to a second pivotal result[2].
Track the Baker cognitive work directly rather than secondhand summaries, and watch for whether anyone registers a longer follow-up trial, because the current cognitive evidence will not hold up as anything more than preliminary until someone does[3].
Growth hormone went through this exact cycle decades ago: chased by athletes in the 1990s on the strength of what it did for genuinely deficient patients, marketed for benefits it was never trialed for, and sorted out only once regulators and researchers separated the approved use from the hype. Tesamorelin is running the same course, just faster, because forums move quicker than the rumor mill ever did. The visceral-fat data is real. The rest of what people want it to do still needs a trial that hasn’t been run.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England journal of medicine, 2007.
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. The lancet. HIV, 2019.
Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.. Archives of neurology, 2012.
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.. The lancet. Diabetes & endocrinology, 2024.
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.. The Journal of clinical endocrinology and metabolism, 2021.
